The research, published in BMC Geriatrics , examined clinicians’ views on what, how and why neuropsychological assessment results are communicated. The investigators conducted two focus groups with physicians and two focus groups with psychologists. Participants were experienced clinicians working in Dutch memory clinics, and two independent researchers analysed the accounts using deductive thematic content analysis.

This design explored professional perspectives through qualitative discussion; it did not measure patient outcomes or establish whether any particular communication strategy improves understanding, disease acceptance or clinical care. Participants described neuropsychological assessments as central to memory-clinic diagnostics and closely integrated with other diagnostic tests. Because these assessments provide detailed information about cognitive functioning and daily life, clinicians said they use the results as part of a broader diagnostic explanation rather than communicating them in isolation.

Their accounts emphasized personalized, structured disclosure, with strategies aimed at helping recipients understand the findings and manage emotional responses. The findings show that clinicians view neuropsychological assessment not only as a diagnostic instrument but also as a resource for matching communication to the people receiving the results. Clinicians also placed the disclosure within a wider process.

Although they saw disease acceptance as extending beyond the memory clinic, they recognized that communication during the diagnostic or neuropsychological disclosure may influence how patients first understand and adjust to information about a possible neurodegenerative disease. The authors conclude that optimizing how results are conveyed may improve patient understanding and the quality of memory-clinic care.

Subject of Research: How Dutch memory-clinic professionals communicate neuropsychological assessment results to patients and informal caregivers

Article Title: Communicating neuropsychological assessment results: a qualitative study in Dutch memory clinic professionals

Article References: Stolte, M., Dobbe, J. H. M., Visser, L. N. C., Smets, E., Jansen, W. J., de Vugt, M., & Ramakers, I. (2026). Communicating neuropsychological assessment results: a qualitative study in Dutch memory clinic professionals. BMC Geriatrics. https://doi.org/10.1186/s12877-026-08529-w

Image Credits: AI Generated

DOI: 10.1186/s12877-026-08529-w

Keywords: neuropsychological assessment, memory clinics, diagnostic communication, patient understanding, caregiver communication, disease acceptance, qualitative research, focus groups, cognitive functioning, Dutch clinicians, Communicating, neuropsychological

Within the intervention group, observed amplicon sequence variant richness and inverse Simpson diversity both decreased between baseline and week 24, with P values of 0.027 and 0.039, respectively. Neither measure changed significantly over time among controls, for which the corresponding P values were 0.464 and 0.812. Weighted UniFrac beta diversity, which assessed differences in bacterial community composition, also shifted significantly within the intervention group (P < 0.001), while the change among controls was not significant (P = 0.193). A dysbiosis index decreased within the intervention group (P < 0.001), consistent with a shift toward the study’s healthy reference microbiome configuration; the corresponding change among controls was not significant (P = 0.372).

Integrated analyses identified 19 genera showing directionally consistent changes in the intervention group. These included enrichment of genera described as producers of short-chain fatty acids, including Faecalibacterium and Butyrivibrio, alongside reductions in members of the Enterobacteriaceae family. The investigators evaluated microbiome composition alongside predicted microbial functional profiles, meaning that the functional findings were estimates based on taxonomic information rather than direct measurements of metabolites or metabolic activity. The study therefore reported a microbial composition consistent with changes in functional potential, but it did not directly establish changes in short-chain fatty acid production or other biological pathways.

Longitudinal changes in several microbial genera were associated with changes in clinical outcomes. These associations showed that particular patterns of microbiome change coincided with changes in cognitive or physical-function measures, but the analysis did not demonstrate that the microbial changes caused the clinical changes. Similarly, the microbiome findings cannot be said to account for the greater RBANS improvement observed in the intervention group, because the study did not establish that microbiome remodeling mediated the treatment effect. Its design supports characterization of associations within this trial rather than a definitive mechanistic explanation of how the lifestyle program influenced cognition.

The researchers separately assessed whether baseline microbiome and clinical information could identify participants who would respond to the intervention, defined as an RBANS improvement greater than zero. An exploratory machine-learning model combined microbiome composition with clinical features and achieved an area under the receiver operating characteristic curve of 0.83. Baseline Short Physical Performance Battery score and Eubacterium abundance were the strongest contributors. This performance was reported from the study sample rather than an independent validation cohort, making the result preliminary and limiting its generalizability. The study was also exploratory in scope, and the authors called for larger investigations incorporating multi-omics approaches and independent cohorts to confirm the findings and clarify the mechanisms underlying the associations between microbial change, physical function and cognitive response.

Subject of Research: Associations between a multidomain lifestyle intervention, gut microbiome changes and cognitive outcomes in older adults at risk of dementia.

Article Title: Longitudinal changes in the gut microbiome following a multidomain lifestyle intervention in older adults at risk of dementia: an exploratory sub-study of the SUPERBRAIN trial

Article References: Yoon, C. W., Kang, W., Lee, J.-Y., Sung, H., Oh, H.-S., Hyun, D.-W., Jeong, J. H., Na, H. R., Moon, S. Y., Hong, C. H., Park, Y. K., & Choi, S. H. (2026). Longitudinal changes in the gut microbiome following a multidomain lifestyle intervention in older adults at risk of dementia: an exploratory sub-study of the SUPERBRAIN trial. BMC Geriatrics. https://doi.org/10.1186/s12877-026-08421-7

Image Credits: AI Generated

DOI: 10.1186/s12877-026-08421-7

Keywords: gut microbiome, multidomain intervention, older adults, dementia risk, cognitive function, 16S rRNA sequencing, microbiome diversity, SUPERBRAIN trial, machine learning, exploratory study, Longitudinal, changes

The scale of the improvement is what makes the trial striking. Within the experimental group, children showed statistically significant gains in attention and executive function performance across the board, with all within-group comparisons reaching the p ≤ 0.01 threshold. By contrast, the control group showed essentially no meaningful change over the same twelve weeks, with the notable exception of a decline: their performance on the More-Odd Shifting Task, a measure of cognitive flexibility, actually got significantly worse over the study period, at p < 0.001. That divergence between the two groups is important because cognitive flexibility, the ability to shift between different tasks or mental sets, is one of the executive functions that children with autism often struggle with most, and a passive waitlist-style period appears to have allowed those difficulties to deepen while the art intervention group was moving in the opposite direction.

Executive function is an umbrella term that cognitive scientists use to describe a family of higher-order mental processes governed largely by the prefrontal cortex. These include working memory, inhibitory control, cognitive flexibility, and the ability to plan and monitor goal-directed behavior. For children with autism spectrum disorder, deficits in these domains are among the most consequential features of the condition, predicting difficulties with academic achievement, social interaction, and daily independence. Prior research has documented that executive function impairments in autistic preschoolers are closely related to the severity of core autism symptoms, and a 2024 review in Nature Reviews Psychology placed executive function deficits at the center of the cognitive profiles shared by autism and attention-deficit/hyperactivity disorder. Any intervention that can move the needle on these abilities during early development therefore carries considerable clinical weight.

Attention, meanwhile, has long been recognized as a foundational area of difficulty in autism. Studies stretching back decades have described both atypical attentional orienting and impaired sustained attention in autistic children, and these attentional differences are thought to cascade into broader developmental outcomes, affecting everything from language acquisition to joint attention skills. The trial’s outcome battery drew on computerized neuropsychological assessment in the tradition of the Amsterdam Neuropsychological Tasks, a well-established computer-aided assessment platform, alongside tasks such as the Schulte grid-based visual search paradigm, which has been used in event-related potential studies to probe the neural mechanisms of visual attention. Measuring eight separate attention and executive function outcomes gave the researchers a multidimensional picture of cognitive change rather than relying on a single summary score.

Why would painting, music, and other art forms reach into cognitive machinery as fundamental as attention and executive control? The authors situate their work within a growing body of neuroscience suggesting that artistic activity engages the brain in distinctive ways. A landmark 2014 study using functional connectivity imaging found that visual art production, as opposed to mere cognitive evaluation of art, produced measurable changes in functional brain connectivity, particularly in networks associated with self-reflection and cognitive control. Music therapy research has similarly documented effects on sensory gating and attention in autistic children, with pilot studies suggesting that rhythmic, structured musical engagement may help regulate the sensory filtering processes that are often atypical in autism. The Therapeutic Music Capacities Model, proposed in 2020, argues that music’s therapeutic power for neurological disorders stems from its unique combination of emotional salience, temporal structure, and social synchrony, all of which place demands on attention and self-regulation.

The multimodal design of the intervention is also theoretically significant. Rather than isolating a single artistic medium, the program combined multiple art forms across its ninety-minute sessions, engaging visual, auditory, and motor systems simultaneously. This matters because self-determination theory, a leading motivational framework, holds that activities which satisfy children’s needs for autonomy, competence, and relatedness sustain engagement far better than drill-based training, and art activities are intrinsically motivating in a way that many cognitive training exercises are not. Previous reviews of art interventions for autistic children, including a 2022 scoping review in the American Journal of Occupational Therapy and a 2025 systematic review in the International Journal of Art Therapy, have noted that the field suffers from a shortage of rigorous randomized controlled trials. Most existing evidence comes from case studies, single-group pre-post designs, or small pilots, which makes the new trial’s randomized, controlled architecture a meaningful methodological step forward.

The trial also adds to a broader scientific conversation about the cognitive benefits of combined physical and artistic engagement. Exercise interventions have themselves been shown in meta-analyses to improve executive function in children and adolescents with autism, and cognitively engaging physical activity has demonstrated time-course effects on self-control in school-aged children in recent randomized trials. The control group in this study continued routine physical activities, which means the observed advantage for the art group cannot be attributed simply to movement or novelty. Instead, the findings point toward something specific about the artistic modality itself, whether that is the sustained visual attention demanded by drawing, the auditory attention and temporal prediction required by music, or the planning and inhibition involved in completing a creative project from start to finish.

The researchers are careful about the limits of what their study can claim. They acknowledge that the underlying mechanisms by which multimodal art intervention improves attention and executive function remain unclear, and they call for future research to explore whether the intervention works across the full range of autism severity, from mild to moderate to severe presentations. The sample of forty-two children, while adequate for detecting the effects observed, is modest by the standards of large multi-site trials, and the children were recruited from a single local autism association, which raises questions about how generalizable the findings are to the wider autistic population. The authors also note that the field of autism intervention research more broadly has faced scrutiny over effect replication, with large meta-analytic projects such as Project AIM highlighting how often intervention effects on developmental outcomes shrink or vanish under rigorous evaluation.

Even with those caveats, the trial arrives at a moment of pressing need. Surveillance data from the United States Centers for Disease Control and Prevention’s Autism and Developmental Disabilities Monitoring Network indicate that autism prevalence continues to rise, with recent estimates showing substantial numbers of children aged four and eight identified with autism across sixteen monitored sites. Early intensive behavioral intervention remains the best-validated approach for young autistic children, but it is resource-intensive, and families and clinicians have long sought complementary, engaging, and low-burden options. Art therapy and music therapy are already widely used in educational and clinical settings for autistic children, yet until recently the evidence base supporting them has been thin. A randomized controlled trial showing broad cognitive gains, with effects surviving multiple-comparison corrections across eight separate outcomes, gives practitioners and policymakers something they have rarely had in this domain: controlled experimental evidence rather than anecdote.

The study, conducted by Qi-Fan Wu and Jia-Qi Du of the College of Physical Education at Anhui Normal University in China and published online on 13 October 2026, received no external funding and was approved by the university’s ethics committee, with informed consent obtained from the parents or guardians of all participants. Its central message is deceptively simple: a structured program of creative activity, delivered consistently over twelve weeks, was associated with measurable improvements in some of the most consequential cognitive abilities that autistic children need for learning and daily life. If future studies replicate these findings in larger and more diverse samples and begin to illuminate the neural mechanisms at work, multimodal art intervention could move from the margins of complementary therapy into the evidence-based mainstream of autism care, offering a joyful and accessible route to cognitive support during the early developmental window when intervention matters most.

Subject of Research: Effects of a multimodal art intervention on attention and executive function in children with autism spectrum disorder

Article Title: Enhancing Attention and Executive Function in Children With Autism Spectrum Disorder: A Randomized Controlled Trial of a 12-Week Multimodal Art Intervention

Article References: Wu, Q.-F., & Du, J.-Q. (2026). Enhancing Attention and Executive Function in Children With Autism Spectrum Disorder: A Randomized Controlled Trial of a 12-Week Multimodal Art Intervention. Journal of Autism and Developmental Disorders. https://doi.org/10.1007/s10803-026-07569-w

Image Credits: AI Generated

DOI: 10.1007/s10803-026-07569-w

Keywords: autism spectrum disorder, multimodal art intervention, attention, executive function, randomized controlled trial, art therapy, music therapy, cognitive flexibility, children, neuropsychological assessment, early intervention, Journal of Autism and Developmental Disorders

The appeal of using dogs to study brain aging is not sentimental; it is scientific. Dogs share our homes, our air, and in many cases our couches, which means they are exposed to many of the same environmental influences that shape human health. They also develop age-related neuropathology that resembles aspects of human dementia, including the accumulation of amyloid-related pathology and declines in hippocampal and prefrontal function. Yet unlike laboratory rodents, dogs live rich, variable lives, and unlike humans, they age on a compressed timescale of years rather than decades. A seven-year-old dog is already entering the window in which subtle cognitive differences begin to emerge, making the species uniquely positioned for longitudinal studies that would take a lifetime to complete in people.

The problem, until now, has been measurement. Existing canine cognitive assessments tend to rely heavily on owner questionnaires, which capture noticeable dysfunction but often only after decline is well established. Others are laboratory-based batteries that require specialized equipment, extensive animal training, or repeated visits that community dogs and their owners cannot easily accommodate. CANID was designed to thread this needle: a functional evaluation consisting of three cognitive tasks that probe memory and executive function, the very domains that erode earliest in human aging, deliverable in a single session of roughly forty minutes, and suitable for dogs living in ordinary homes rather than research colonies.

The technical architecture of the battery reflects decades of work in human neuropsychology. Executive function, the umbrella term for the cognitive control processes mediated largely by prefrontal cortex, is assessed through tasks requiring behavioral inhibition, attention, and problem-solving under changing rules. Memory components tap working memory and the ability to hold and manipulate information across short delays. Each task yields a subscore, and the subscores combine into an overall CANID score, giving researchers both a sensitive global index and finer-grained domain-specific measures. This structure mirrors the logic of human test batteries, in which a single composite score can track broad decline while individual subscores localize which cognitive systems are faltering.

Validation is where most new behavioral measures stumble, and where CANID makes its strongest case. The team developed their scoring system using a baseline sample of 239 dogs, then brought the same animals back for repeat testing at six months, with 138 dogs returning, and again at twelve months, with 114 dogs completing the full arc. Repeatability, the statistical property that a measure returns similar values when the underlying trait has not changed, was quantified using intraclass correlation coefficients, or ICCs. The overall CANID score showed substantial repeatability at six months, with an ICC of 0.63 and a 95 percent confidence interval spanning 0.51 to 0.72, and remained substantial at twelve months, with an ICC of 0.59 and a confidence interval of 0.47 to 0.70. Critically, every task-specific subscore also demonstrated substantial repeatability, indicating that the individual cognitive measures, not just the composite, are stable enough for longitudinal research.

Those numbers deserve unpacking for anyone who has not spent time with psychometrics. An ICC of 0.63 means that roughly 63 percent of the variance in test scores at follow-up can be attributed to stable differences between individual dogs rather than measurement noise or day-to-day fluctuation. In behavioral research, where a single anxious morning or an interesting smell outside the testing window can derail a session, that level of stability is genuinely difficult to achieve. It means a researcher can administer CANID today, administer it again in six months, and have reasonable confidence that any change in score reflects change in the dog rather than change in the instrument. Without that property, longitudinal studies of cognitive aging would be chasing statistical ghosts.

The sensitivity findings may prove even more consequential. CANID detected age-related cognitive differences beginning in mid-life, well before the point at which owners would typically report concerns or questionnaires would flag dysfunction. This matters because the scientific consensus in human Alzheimer’s research has shifted decisively toward early detection: by the time clinical symptoms appear, the underlying pathology has been accumulating for years or decades. A canine measure that registers subtle decline years before overt impairment gives researchers a much wider window in which to study the trajectory of aging, test interventions, and identify predictors of who will decline fastest. In the compressed canine lifespan, that window is measured in precious months and years.

One of the study’s more honest findings concerns practice effects, the improvement in test scores that comes simply from having taken a test before. At the six-month follow-up, dogs showed a modest practice effect of 0.23 standard deviations improvement in overall score relative to baseline, a magnitude the authors note is similar to what has been reported in human studies. Intriguingly, no evidence for practice effects emerged at the one-year follow-up, suggesting the familiarity advantage fades with time. For researchers, this is both a warning and a gift: it means six-month comparisons should account for the expected bump, but it also means the effect is predictable, quantified, and consistent with the human literature, making it manageable rather than fatal to longitudinal designs.

The team has also made an unusually strong commitment to open science. To facilitate adoption, they have released detailed protocols, video libraries, data recording instruments, experimenter training guidelines, and R code for scoring in an Open Science Framework repository. This is not a trivial gesture. Behavioral measures live or die on standardization, and the history of comparative cognition is littered with tasks that produced inconsistent results because each laboratory implemented them slightly differently. By providing video libraries that show exactly how testing should look and code that automates scoring, the authors are attempting to ensure that a CANID score from one lab means the same thing as a CANID score from another, a prerequisite for the large multi-site studies that cognitive aging research increasingly demands.

The work was carried out within the framework of the Dog Aging Project, a large-scale longitudinal study of companion dogs supported in part by the National Institute on Aging, with additional support from the Glenn Foundation for Medical Research, the Tiny Foundation Fund at Myriad Canada, the WoodNext Foundation, and the Dog Aging Institute. All procedures were approved by the University of Arizona Institutional Animal Care and Use Committee, and testing was designed with welfare in mind: data collection was discontinued if dogs became fearful or anxious and could not be soothed, and no testing occurred with dogs who could not acclimate within roughly fifteen minutes of arrival. Written consent was obtained from all owners.

What comes next could be transformative for both veterinary and human medicine. With a validated, efficient, and repeatable measure in hand, researchers can begin tracking thousands of dogs across their lifespans, correlating cognitive trajectories with genetics, diet, exercise, and eventual neuropathological findings. Dogs could serve as a bridge species in which candidate interventions for human dementia are tested under ecologically realistic conditions, and veterinarians could gain a practical tool for identifying cognitive decline in clinical practice years before it becomes obvious to owners. For the millions of aging dogs sharing homes around the world, and for the humans who love them, a forty-minute test may quietly change what it means to grow old together.

Subject of Research: A validated cognitive test battery for detecting age-related neuropsychological impairment in dogs

Article Title: Cognitive assessment for neuropsychological impairments in dogs (CANID): an efficient, repeatable, and sensitive evaluation for studies of cognitive aging

Article References: Hargrave, S. H., Bray, E. E., Switzer, L. R., McGrath, S., Alexander, G. E., Block, T., Carranza, E., Chao, N., Douglas, L. E. L. C., Galante, J., Hilyard, E., Jonkoski, D., Kennedy, B. S., Kristal, E., Moreno, J. A., Promislow, D. E. L., Raichlen, D. A., Stetson, N., Tereso, K., … MacLean, E. L. (2026). Cognitive assessment for neuropsychological impairments in dogs (CANID): an efficient, repeatable, and sensitive evaluation for studies of cognitive aging. Animal Cognition. https://doi.org/10.1007/s10071-026-02112-x

Image Credits: AI Generated

DOI: 10.1007/s10071-026-02112-x

Keywords: cognitive aging, dogs, CANID, neuropsychological assessment, executive function, memory, Dog Aging Project, animal cognition, repeatability, dementia, open science, veterinary science

The study, led by Fang-Tzu Chuang of Asia University and Ko-Ting Chen of Chang Gung Memorial Hospital, together with colleagues at several Taiwanese institutions, enrolled sixty-five patients who had been newly diagnosed with glioma and had not yet received any treatment. Thirty of them had experienced tumor-related epilepsy, meaning seizures caused directly by the tumor, while thirty-five had not. This treatment-naive design matters enormously for interpreting the results. Once patients undergo surgery, radiation, or chemotherapy, and once they begin taking antiseizure medications, it becomes nearly impossible to disentangle the effects of the tumor itself from the effects of the interventions. By testing cognition before any treatment began, the researchers obtained a snapshot of what the tumor and the brain’s response to it were doing on their own.

The neuropsychological battery was comprehensive. Patients completed measures of attention, processing speed, executive function, memory, language, and visuospatial ability, including the Trail Making Test, the Wechsler Adult Intelligence Scale, the Benton Visual Retention Test, and Nelson’s Modified Card Sorting Test, among others. Crucially, rather than comparing raw scores, the team converted each patient’s performance into percentile ranks adjusted for demographic factors such as age and education. This approach allows a fair comparison between, say, a twenty-five-year-old university graduate and a sixty-year-old patient with fewer years of schooling, both of whom may be functioning normally or abnormally relative to their own demographic peers.

Before any statistical correction, the picture looked striking. Patients with tumor-related epilepsy were younger, more highly educated, had smaller enhancing tumor volumes on imaging, were more likely to have lower-grade tumors, and carried isocitrate dehydrogenase, or IDH, mutations far more often. Each of these characteristics is independently associated with better cognitive outcomes in the glioma literature. IDH-mutant gliomas, in particular, are known to behave more indolently and to be associated with preserved neurological function, and prior work has linked the mutation to a higher incidence of preoperative seizures, possibly through the accumulation of the oncometabolite D-2-hydroxyglutarate, which can promote hyperexcitability in surrounding neural tissue. On several cognitive measures, the seizure group simply outperformed the non-seizure group.

But raw group differences can be deceptive when the groups differ in so many other ways. To address this, the researchers applied the Benjamini-Hochberg false discovery rate correction, a statistical procedure designed to limit the number of spurious positive findings when many tests are run simultaneously. After this correction, only one measure survived: Part A of the Trail Making Test, a timed task in which the patient connects numbered circles in sequence. The test is a sensitive index of visual scanning, attention, and psychomotor speed. Patients with tumor-related epilepsy scored at a median percentile of 83, meaning they performed better than roughly eighty-three percent of demographically matched healthy individuals, while patients without seizures scored at a median percentile of 21. The effect size, expressed as r = .41, is moderate to large by conventional standards, and the corrected significance value was q = 0.04.

The more demanding question was whether the seizure-cognition link would survive adjustment for the confounding variables. In a multivariable regression model that included age and enhancing tumor volume, seizure presentation remained significantly associated with better TMT-A performance, with a standardized coefficient of B = 0.276 and a p-value of .017. In sensitivity analyses that additionally incorporated IDH mutation status and other demographic and clinicopathological characteristics, the association held firm. This persistence is the study’s central message. If the apparent cognitive advantage of seizure patients were merely a proxy for youth, education, small tumors, low grade, or favorable molecular profile, it should have dissolved once those variables entered the model. Instead, it endured, implying that the seizure itself, or the biology that produces it, marks something clinically meaningful about how the tumor interacts with the brain.

What could that something be? The authors and the broader literature point toward several candidate mechanisms. One possibility relates to tumor location and growth pattern. Slow-growing, diffuse tumors that infiltrate functional cortex gradually may be more likely to irritate neural circuits into seizure activity while leaving cognitive networks relatively intact, whereas rapidly expanding masses in non-eloquent regions may reach considerable size silently, compressing and disrupting tissue without ever triggering epileptiform discharges. Work on glioblastoma has shown that patients presenting with seizures differ microstructurally and volumetrically from those without, and recent research has even linked seizure presentation in IDH-wildtype glioblastoma to the upregulation of a synaptic gene signature, hinting that epileptogenic tumors may inhabit a different biological niche than their non-epileptogenic counterparts.

The metabolic dimension adds further intrigue. IDH-mutant gliomas produce D-2-hydroxyglutarate, an oncometabolite detectable by magnetic resonance spectroscopy, and elevated levels of this molecule have been associated with preoperative seizures. Animal and cellular studies suggest that D-2-hydroxyglutarate promotes epileptogenesis through hyperactivation of the mTOR signaling pathway, which regulates synaptic plasticity. In this framework, the very biochemistry that makes a glioma epileptogenic also tends to make it slower-growing and less aggressive, which could explain why seizure patients arrive at the clinic with better-preserved processing speed. The seizure, in this reading, is not a cause of better cognition but a visible symptom of a tumor biology that is, paradoxically, gentler to the mind.

The clinical implications are worth spelling out. Preoperative cognitive performance is one of the strongest predictors of quality of life, employment status, and even survival in glioma patients; studies have shown that initial cognitive impairment predicts shorter survival in glioblastoma. If seizure presentation reliably flags a distinct cognitive and biological profile, neurosurgeons and neuro-oncologists could use that information when planning the extent of resection, counseling patients about prognosis, and designing cognitive rehabilitation programs. A patient who presents with seizures and strong processing speed may tolerate more aggressive surgical strategies aimed at long-term control, whereas a patient arriving with silent tumor growth and already-impaired cognition may require a different calculus. The finding also cautions against the reflexive assumption that seizures in brain tumor patients are uniformly bad news for the brain.

The researchers are careful to frame the work as preliminary. Sixty-five patients is a modest sample, and the single-center design in Taiwan raises questions about generalizability, although the use of locally validated normative data for the neuropsychological instruments strengthens the demographic adjustments. The study also did not generate or analyze external datasets, and the authors note that the mechanisms linking epileptogenesis to cognitive preservation remain to be tested directly, perhaps through longitudinal follow-up, functional connectivity imaging, or metabolic spectroscopy. Still, the core result is clean and statistically disciplined: after correcting for multiple comparisons and adjusting for the obvious confounders, seizure presentation retained a significant association with better processing speed. That suggests tumor-related epilepsy is not just a symptom to be suppressed but a signal to be read, a clinical clue that the tumor-brain context of one patient may differ in kind, not merely in degree, from that of another. For a disease as heterogeneous and unforgiving as glioma, every such clue counts.

Subject of Research: The association between tumor-related epilepsy and preoperative cognitive performance in patients with glioma

Article Title: Tumor-related epilepsy and preoperative cognitive performance in glioma: a preliminary study

Article References: Chuang, F.-T., Chen, K.-T., Wei, K.-C., Chen, Y.-C., Wang, W.-H., Liao, Y.-C., & Chang, H.-T. (2026). Tumor-related epilepsy and preoperative cognitive performance in glioma: a preliminary study. Journal of Neuro-Oncology, 180(1), Article 11. https://doi.org/10.1007/s11060-026-05820-z

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05820-z

Keywords: glioma, tumor-related epilepsy, neuropsychological assessment, Trail Making Test, IDH mutation, processing speed, cognitive function, brain tumor, epileptogenesis, D-2-hydroxyglutarate, neuro-oncology, preoperative cognition

The research team, led by Qinghua Guo, Yong Wang, Chuan Shi, and Shaomei Shang, followed 136 adults undergoing an acute course of ECT in a real-world clinical setting. Each participant completed the ECT-CI and the Montreal Cognitive Assessment, better known as the MoCA, at three time points: before treatment began, within 48 hours after the acute course ended, and again at a three-month follow-up. Crucially, the study did not rely on test scores alone to define impairment. Blinded psychiatrists adjudicated whether each patient met criteria for cognitive impairment using a framework based on the DSM-5-TR, the current edition of the American Psychiatric Association’s diagnostic manual, and those clinician judgments served as the reference standard against which both instruments were judged.

The clinical picture that emerged was sobering. Clinician-adjudicated cognitive impairment rose from 12.5 percent of patients at baseline to 33.1 percent immediately after the acute treatment course, and then climbed further to 50.7 percent at the three-month follow-up. That trajectory, in which the proportion of patients judged cognitively impaired continues to rise well after the last seizure has been induced, underscores how incomplete our understanding of post-ECT cognition remains. Many patients do not simply recover in a straight line after treatment ends, and some appear to experience worsening difficulties that only become apparent weeks later, a pattern that brief in-hospital testing at discharge would entirely miss.

Against this backdrop, the performance of the two cognitive instruments diverged in ways that matter for everyday practice. ECT-CI scores fell from baseline to the post-course assessment and then partially rebounded at follow-up, and the magnitude of those observed score changes was larger than what the MoCA captured over the same period. The ECT-CI also took less time to administer, a nontrivial advantage at the bedside of acutely ill psychiatric inpatients. At the domain level, the inventory registered changes in memory, executive function, and caregiver-rated cognition, offering a multidimensional view of how patients were actually functioning rather than a single composite number. In statistical comparisons of discrimination, essentially the ability of a test score to separate patients who have impairment from those who do not, the ECT-CI outperformed the MoCA against the clinician-adjudicated reference standard at every assessment point.

Perhaps the most clinically consequential finding concerned prediction. Baseline ECT-CI scores showed greater prognostic discrimination than baseline MoCA scores for identifying which patients would meet the clinician-adjudicated criteria for cognitive impairment three months later. In practical terms, this means a brief test administered before the first seizure could help clinicians flag patients at elevated risk of lasting cognitive difficulty, opening a window for interventions that do not currently exist in routine care: closer monitoring, adjusted treatment parameters, or earlier supportive measures. The MoCA, designed as a general screen for dementia and delirium across clinical populations, simply was not built to detect the specific, often subtle cognitive signature that ECT produces.

To move beyond averages and capture the diversity of individual recovery patterns, the researchers turned to growth mixture modelling, a statistical technique that identifies hidden subgroups within a population based on how their scores change over time. The analysis revealed three distinct ECT-CI trajectories. One group maintained high, stable scores throughout, suggesting resilience to the cognitive effects of treatment. A second group experienced an acute decline in scores immediately after the treatment course followed by a partial rebound at follow-up, a pattern consistent with transient, treatment-related effects that fade with time. The third and most concerning group started from a low baseline and suffered a marked acute decline, entering treatment already cognitively vulnerable and deteriorating further.

Who ended up in that worst trajectory was not random. Lower baseline MoCA scores and a diagnosis of schizophrenia were associated with membership in the low-baseline, marked-decline group. This finding carries real weight for treatment planning. Patients with schizophrenia who undergo ECT, often for refractory symptoms, may represent a population in whom cognitive reserve is already diminished and in whom the additional burden of a treatment course pushes function below a critical threshold. The results support a model of risk-stratified cognitive monitoring, in which patients are assessed before treatment and assigned to different intensities of follow-up based on their baseline profile and diagnostic background, rather than receiving a uniform, one-size-fits-all check.

The study also ventured into territory that has attracted growing interest across neuropsychiatry: the role of inflammation. In exploratory analyses, the researchers examined systemic immune-inflammatory markers, including the systemic immune-inflammation index and related indices derived from routine blood counts, along with C-reactive protein, a well-known marker of systemic inflammation. Their analyses suggested that systemic immune-inflammatory burden characterized the unfavourable cognitive trajectories, and, intriguingly, that baseline CRP levels interacted with the cumulative ECT charge, the total amount of electrical stimulation a patient received over the course. In other words, the relationship between how much stimulation a patient’s brain absorbed and whether that patient developed clinician-adjudicated cognitive impairment appeared to depend on the inflammatory state of the body before treatment began.

These inflammatory findings must be read with appropriate caution, as the authors themselves frame them as exploratory, and a single cohort study cannot establish mechanism. But the underlying hypothesis is biologically plausible and resonates with a broader literature linking neuroinflammation to vulnerability of the hippocampus and other memory-critical structures. If confirmed in independent samples, the idea that inflammatory status modifies the cognitive cost of cumulative electrical stimulation could reshape how clinicians think about dosing strategies. It might eventually support the use of inexpensive blood tests, already drawn routinely in pre-ECT workups, as part of a personalized risk assessment, and it could motivate trials of anti-inflammatory or lifestyle interventions aimed at lowering inflammatory burden before an elective treatment course.

What the study delivers most concretely is a validation case for disease-specific measurement. The ECT-CI tracked score changes that the MoCA missed, discriminated better against a rigorous clinical reference standard, predicted three-month outcomes from baseline, and lent itself to trajectory-based risk stratification, all while requiring less administration time. For a procedure administered to hundreds of thousands of patients worldwide each year, the absence of a dedicated cognitive monitoring standard has been a conspicuous gap. This prospective real-world cohort, registered with the Chinese Clinical Trial Registry and conducted under ethics approval at Peking University Sixth Hospital, provides the strongest longitudinal evidence to date that filling that gap is both feasible and clinically worthwhile. The next steps, replication in larger and more diverse populations, external validation of the three-trajectory model, and prospective testing of whether risk-stratified monitoring actually improves patient outcomes, will determine whether the ECT-CI moves from promising research instrument to standard of care. For now, the message for clinicians is clear: when it comes to the cognitive price of electroconvulsive therapy, the right questions, asked with the right tool, reveal risks that general screening has been quietly missing.

Subject of Research: Longitudinal validation of the ECT-CI for monitoring cognitive impairment after electroconvulsive therapy

Article Title: Longitudinal evaluation of the ECT-CI after electroconvulsive therapy: score changes, clinical discrimination, and latent score trajectories in a prospective real-world cohort

Article References: Guo, Q., Wang, Y., Guo, L., He, X., Pu, C., Shi, C., & Shang, S. (2026). Longitudinal evaluation of the ECT-CI after electroconvulsive therapy: score changes, clinical discrimination, and latent score trajectories in a prospective real-world cohort. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08718-2

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08718-2

Keywords: electroconvulsive therapy, ECT-CI, cognitive impairment, MoCA, growth mixture modelling, prognostic discrimination, inflammation, CRP, psychiatry, neuropsychological assessment, schizophrenia, longitudinal cohort